Strategy
Portfolio
People
Careers
News
Blog
Contact Us
December 10, 2020
Remix Therapeutics debuts with $81M to ‘reprogram’ disease-causing RNA
Back
Portfolio News
Next
Back
Blog
Next
News
Blog
Foresite Labs
Contact Us
Home
Strategy
Portfolio
People
Careers
News
Blog
Contact Us
Foresite Labs
Investor Login
Terms
Privacy Policy
Blog
Careers
Contact Us
Disclosures
Home
Legal Disclaimers
Pardes Biosciences Legend
Privacy Policy
Strategy
Terms
©2023 Foresite Capital Management, LLC.
Site by Goodlab
